



AUG 22 2005

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: August 16, 2005

Signature: \_\_\_\_\_

(Cristin E. Howley, Ph.D.)

Docket No.: KZI-001US  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Ernest Loumaye

Application No.: 10/540228

Confirmation No.: 1620

Filed: June 21, 2005

Art Unit: N/A

For: USE OF GNRH AGONISTS TO SUPPORT  
THE LUTEAL PHASE DURING  
INFERTILITY TREATMENT

Examiner: Not Yet Assigned

**INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:


Applicant and their Agent are aware of the following publications and information, listed on the attached PTO Form SB/08, and in accordance with 37 CFR §1.97 hereby submit these publications for the Examiner's consideration. Copies of the documents cited are enclosed with this statement. A copy of the International Search Report is also enclosed.


This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicant understand that the Examiner will make an independent evaluation of the cited publications.

Under 37 CFR § 1.97(b)(1), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR §1.17(p) to our Deposit Order Account No. 12-0080.

Dated: August 16, 2005

Respectfully submitted,

By   
Cristin E. Howley, Ph.D.  
Registration No.: 55,281  
LAHIVE & COCKFIELD, LLP  
28 State Street  
Boston, Massachusetts 02109  
(617) 227-7400  
(617) 742-4214 (Fax)  
Agent For Applicant



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/540228
				Filing Date	June 21, 2005
				First Named Inventor	Ernest LOUMAYE
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	KZI-001US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	B1	WO 95/16459	06/22/1995	PCT		


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	LEMAY, Andre <i>et al.</i> "Sensitivity of pituitary and corpus luteum responses to single intranasal administration of (D-Ser[TBU] <sup>6</sup> -des-Gly-NH <sub>2</sub> <sup>10</sup> ) luteinizing hormone-releasing hormone ethylamide (Buserelin) in normal women" <i>Fertility and Sterility</i> , 37(2):193-200 (1982)	
	C2	MOLLOY, Brian <i>et al.</i> "Ovulation induction in clomiphene nonresponsive patients: the place of pulsatile gonadotropin-releasing hormone in clinical practice" <i>Fertility and Sterility</i> , 43(1):26-33 (1985)	
	C3	LEMAY, Andre <i>et al.</i> "Gonadotroph and corpus luteum responses to two successive intranasal doses of a luteinizing hormone-releasing hormone agonist at different days after the midcycle luteinizing hormone surge" <i>Fertility and Sterility</i> , 39(5):661-667 (1983)	
	C4	SCHMIDT-SAROSI, Cecilia <i>et al.</i> "Ovulation triggering in clomiphene citrate-stimulated cycles: human chorionic gonadotropin versus a gonadotropin releasing hormone agonist" <i>Journal of Assisted Reproduction and Genetics</i> , 12(3):167-174 (1985)	
	C5	HANKER, J.P. <i>et al.</i> "Frequency-varied versus unvaried pulsatile LH-RH substitution in hypothalamic amenorrhea" <i>Europ. J. Obstet. Gynec. reprod. Biol.</i> , 17:103-119 (1984)	
	C6	VOLPE, A. <i>et al.</i> "Pregnancy following combined growth hormone-pulsatile GnRH treatment in a patient with hypothalamic amenorrhoea" <i>Human Reproduction</i> , 5(3):345-347 (1990)	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



PTO/SB/92 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 10/540228


Attorney Docket No.: KZI-001US

## Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on August 16, 2005  
Date



Signature

Cristin E. Howley, Ph.D.

Typed or printed name of person signing Certificate

55,281  
Registration Number, if applicable

(617) 227-7400  
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Transmittal Form (1 page)  
Information Disclosure Statement (2 pages)  
PTO Form SB/08 (1 page)  
Copy of References B1 and C1-C6  
Copy of International Search Report (8 pages)  
Return Receipt Postcard